$RGBP The Company's focus on NR2F6 has two developmental streams. The first area of development involves the inhibition of the checkpoint, NR2F6, in order to cause the body's immune system to destroy cancer cells. The second area of development involves the activation of NR2F6 which is believed to be a fulcrum for curing such autoimmune diseases as rheumatoid arthritis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.